BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 37127468)

  • 1. Reply to Mauricio Plata, Cesar Diaz Ritter, and Nicolás Badillo's Letter to the Editor re: Gabriela Ilie, Ricardo Rendon, Ross Mason, et al. A Comprehensive 6-mo Prostate Cancer Patient Empowerment Program Decreases Psychological Distress Among Men Undergoing Curative Prostate Cancer Treatment: A Randomized Clinical Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.02.009.
    Ilie G; David Harold Rutledge R
    Eur Urol; 2023 Jul; 84(1):e26-e27. PubMed ID: 37127468
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Gabriela Ilie, Ricardo Rendon, Ross Mason, et al. A Comprehensive 6-mo Prostate Cancer Patient Empowerment Program Decreases Psychological Distress Among Men Undergoing Curative Prostate Cancer Treatment: A Randomized Clinical Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.02.009.
    Plata M; Cesar DR; Badillo N
    Eur Urol; 2023 Jul; 84(1):e24-e25. PubMed ID: 37147212
    [No Abstract]   [Full Text] [Related]  

  • 3. Reply to André Pontes-Silva's Letter to the Editor re: Gabriela Ilie, Ricardo Rendon, Ross Mason, et al. A Comprehensive 6-mo Prostate Cancer Patient Empowerment Program Decreases Psychological Distress Among Men Undergoing Curative Prostate Cancer Treatment: A Randomized Clinical Trial. Eur Urol 2023;83:561-70.
    Ilie G; Rutledge RDH
    Eur Urol; 2024 Feb; 85(2):e45-e46. PubMed ID: 37743197
    [No Abstract]   [Full Text] [Related]  

  • 4. Reply to Zhipeng Mai, Weigang Yan, and Zhien Zhou's Letter to the Editor re: Gabriela Ilie, Ricardo Rendon, Ross Mason, et al. A Comprehensive 6-mo Prostate Cancer Patient Empowerment Program Decreases Psychological Distress Among Men Undergoing Curative Prostate Cancer Treatment: A Randomized Clinical Trial. Eur Urol 2023;83:561-70.
    Ilie G; Rutledge RDH
    Eur Urol; 2023 Aug; 84(2):e48-e49. PubMed ID: 37244817
    [No Abstract]   [Full Text] [Related]  

  • 5. Reply to Matthias May, Ingmar Wolff, and Sabine D. Brookman-May's Letter to the Editor re: Gabriela Ilie, Ricardo Rendon, Ross Mason, et al. A Comprehensive 6-mo Prostate Cancer Patient Empowerment Program Decreases Psychological Distress Among Men Undergoing Curative Prostate Cancer Treatment: A Randomized Clinical Trial. Eur Urol 2023;83:561-70.
    Ilie G; Rutledge RDH
    Eur Urol; 2024 Feb; 85(2):e49-e50. PubMed ID: 37743193
    [No Abstract]   [Full Text] [Related]  

  • 6. Re: Gabriela Ilie, Ricardo Rendon, Ross Mason, et al. A Comprehensive 6-mo Prostate Cancer Patient Empowerment Program Decreases Psychological Distress Among Men Undergoing Curative Prostate Cancer Treatment: A Randomized Clinical Trial. Eur Urol. 2023;83:561-70.
    Mai Z; Yan W; Zhou Z
    Eur Urol; 2023 Aug; 84(2):e46-e47. PubMed ID: 37244814
    [No Abstract]   [Full Text] [Related]  

  • 7. Re: Gabriela Ilie, Ricardo Rendon, Ross Mason, et al. A Comprehensive 6-mo Prostate Cancer Patient Empowerment Program Decreases Psychological Distress Among Men Undergoing Curative Prostate Cancer Treatment: A Randomized Clinical Trial. Eur Urol 2023;83:561-70.
    Pontes-Silva A
    Eur Urol; 2024 Feb; 85(2):e43-e44. PubMed ID: 37758572
    [No Abstract]   [Full Text] [Related]  

  • 8. Re: Gabriela Ilie, Ricardo Rendon, Ross Mason, et al. A Comprehensive 6-mo Prostate Cancer Patient Empowerment Program Decreases Psychological Distress Among Men Undergoing Curative Prostate Cancer Treatment: A Randomized Clinical Trial. Eur Urol 2023;83:561-70.
    May M; Wolff I; Brookman-May SD
    Eur Urol; 2024 Feb; 85(2):e47-e48. PubMed ID: 37743196
    [No Abstract]   [Full Text] [Related]  

  • 9. A Comprehensive 6-mo Prostate Cancer Patient Empowerment Program Decreases Psychological Distress Among Men Undergoing Curative Prostate Cancer Treatment: A Randomized Clinical Trial.
    Ilie G; Rendon R; Mason R; MacDonald C; Kucharczyk MJ; Patil N; Bowes D; Bailly G; Bell D; Lawen J; Ha M; Wilke D; Massaro P; Zahavich J; Kephart G; Rutledge RDH
    Eur Urol; 2023 Jun; 83(6):561-570. PubMed ID: 36822969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reply to Erfan Ayubi and Saeid Safiri's Letter to the Editor re: R. Jeffrey Karnes, Voleak Choeurng, Ashley E. Ross, et al. Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2017.03.036. Methodological Issues.
    Trock BJ; Karnes RJ
    Eur Urol; 2017 Dec; 72(6):e158-e159. PubMed ID: 28576503
    [No Abstract]   [Full Text] [Related]  

  • 11. Re: A Comprehensive 6-mo Prostate Cancer Patient Empowerment Program Decreases Psychological Distress Among Men Undergoing Curative Prostate Cancer Treatment: A Randomized Clinical Trial.
    Majumdar JR; Carlsson SV
    Eur Urol; 2023 Sep; 84(3):349-350. PubMed ID: 37188550
    [No Abstract]   [Full Text] [Related]  

  • 12. Reply to Kamal Kant Sahu's Letter to the Editor re: Veerle H. Groen, Karin Haustermans, Floris J. Pos, et al. Patterns of Failure Following External Beam Radiotherapy With or Without an Additional Focal Boost in the Randomized Controlled FLAME Trial for Localized Prostate Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.12.012.
    Kerkmeijer LGW; Pos FJ; van der Heide UA; Israël B; Draulans C; Haustermans K
    Eur Urol; 2022 Jun; 81(6):e147-e148. PubMed ID: 35339319
    [No Abstract]   [Full Text] [Related]  

  • 13. Reply to Jianhui Du, Yueguang Liu, and Weigang Yan's Letter to the Editor re: Gregory T. Chesnut, Emily A. Vertosick, Nicole Benfante, et al. Role of Changes in Magnetic Resonance Imaging or Clinical Stage in Evaluation of Disease Progression for Men with Prostate Cancer on Active Surveillance. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.12.009.
    Chesnut GT; Vertosick EA; Ehdaie B
    Eur Urol; 2020 Aug; 78(2):e65-e66. PubMed ID: 32386781
    [No Abstract]   [Full Text] [Related]  

  • 14. Reply to Sungeun Kim, Jae Il Shin, and Jonathan Evan Shoag's Letter to the Editor re: Luca F. Valle, Eric J. Lehrer, Daniela Markovic, et al. A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER). Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.11.010.
    Valle LF; Kishan AU
    Eur Urol; 2021 Jul; 80(1):e15-e16. PubMed ID: 33934928
    [No Abstract]   [Full Text] [Related]  

  • 15. Reply to Alessia Cimadamore, Liang Cheng, Antonio Lopez-Beltran, Marina Scarpelli, and Rodolfo Montironi's Letter to the Editor re: Scott Wilkinson, Huihui Ye, Fatima Karzai, et al. Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.03.009: Focus on Intraductal Carcinoma of the Prostate.
    Wilkinson S; Ye H; Lis RT; Sowalsky AG
    Eur Urol; 2021 Sep; 80(3):e83-e84. PubMed ID: 34148711
    [No Abstract]   [Full Text] [Related]  

  • 16. Re: R. Jeffrey Karnes, Voleak Choeurng, Ashley E. Ross, et al. Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2017.03.036.
    Ayubi E; Safiri S
    Eur Urol; 2017 Dec; 72(6):e157. PubMed ID: 28576506
    [No Abstract]   [Full Text] [Related]  

  • 17. Reply to Feng Qi, Zicheng Xu, and Qing Zou's Letter to the Editor re: Andrea Loehr, Arif Hussain, Akash Patnaik, et al. Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.09.010.
    Loehr A; Chowdhury S; Abida W
    Eur Urol; 2023 Mar; 83(3):e78. PubMed ID: 36623951
    [No Abstract]   [Full Text] [Related]  

  • 18. Reply to Glen Denmer Santok and Koon Ho Rha's Letter to the Editor re: Pär Stattin, Fredrik Sandin, Frederik Birkebæk Thomsen, et al. Association of Radical Local Treatment with Mortality in Men with Very High-risk Prostate Cancer: A Semiecologic, Nationwide, Population-based Study. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.07.023.
    Stattin P; Bratt O
    Eur Urol; 2017 Apr; 71(4):e115-e116. PubMed ID: 27720538
    [No Abstract]   [Full Text] [Related]  

  • 19. Reply to Carsten Stephan, Henning Cammann, and Klaus Jung's Letter to the Editor re: Scott A. Tomlins, John R. Day, Robert J. Lonigro, et al. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.04.039.
    Tomlins SA; Groskopf J; Chinnaiyan AM
    Eur Urol; 2015 Nov; 68(5):e108. PubMed ID: 26242717
    [No Abstract]   [Full Text] [Related]  

  • 20. Re: Yaw A. Nyame, Matthew R. Cooperberg, Marcus G. Cumberbatch, et al. Deconstructing, Addressing, and Eliminating Racial and Ethnic Inequities in Prostate Cancer Care. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.03.007.
    Wei Y; Ye D; Zhu Y
    Eur Urol; 2022 Aug; 82(2):e51. PubMed ID: 35599186
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.